Press Releases

MIMETAS to launch Assay Ready product line for Organ-on-a-Chip

March 03, 2020
MIMETAS announces the first product release of her Assay Ready product line: OrganoPlate® Caco-2. Innovative in-vitro models r...
Read more
MIMETAS to launch Assay Ready product line for Organ-on-a-Chip

Sapreme Technologies in a 6.8 M€ EU Alliance

February 20, 2020
Sapreme Technologies in a 6.8 M€ EU Alliance to Develop an Oligonucleotide Delivery Platform Based on Its Proprietary Endosomal...
Read more
Sapreme Technologies in a 6.8 M€ EU Alliance

Macrophage Pharma Expands Executive Team with Chief Scientific Officer and Chief Technology Officer

January 09, 2020
Key hires enhance management for next development phase
Read more
Macrophage Pharma Expands Executive Team with Chief Scientific Officer and Chief Technology Officer

Aglaia Oncology Funds and Sinzer - Grant Thornton Launch Dedicated Life Sciences Impact Measuring and Reporting Suite

December 19, 2019
• Enables visibility for investors of social impact realized by their investments • Suite demonstrates value beyond financial...
Read more
Aglaia Oncology Funds and Sinzer - Grant Thornton Launch Dedicated Life Sciences Impact Measuring and Reporting Suite

InteRNA presents data on drug formulation and mode of action of lead oncology development candidate INT-1B3 at the 15th annual OTS meeting

October 31, 2019
InteRNA presents data on drug formulation and mode of action of lead oncology development candidate INT-1B3 at the 15th annual...
Read more
InteRNA presents data on drug formulation and mode of action of lead oncology development candidate INT-1B3 at the 15th annual OTS meeting

Macrophage Pharma Appoints Dr Anker Lundemose to the Board of Directors

September 26, 2019
Macrophage Pharma Limited has appointed Dr. Anker Lundemose as independent non-executive director.
Read more
Macrophage Pharma Appoints Dr Anker Lundemose to the Board of Directors

Macrophage Pharma appoints Dr Søren Bregenholt as Chief Executive Officer

September 03, 2019
Macrophage Pharma Limited ('MPL') announced today that it has appointed Dr Søren Bregenholt as Chief Executive Officer....
Read more
Macrophage Pharma appoints Dr Søren Bregenholt as Chief Executive Officer

Cristal Therapeutics appoints Dr Werner Cautreels as a new Director and Board Chairman and Andre Verwei as Chief Financial Officer

August 01, 2019
Maastricht, The Netherlands, 1st August 2019 - Cristal Therapeutics, a Phase 2 clinical stage pharmaceutical company developing...
Read more
Cristal Therapeutics appoints Dr Werner Cautreels as a new Director and Board Chairman and Andre Verwei as Chief Financial Officer

Modra Pharmaceuticals Announces First Patients Treated in Phase IIb Metastatic Prostate Cancer Trial

August 01, 2019
AMSTERDAM--(BUSINESS WIRE)--Modra Pharmaceuticals B.V. ("Modra") today announced the start of patient treatment in its Phase II...
Read more
Modra Pharmaceuticals Announces First Patients Treated in Phase IIb Metastatic Prostate Cancer Trial

Cristal Therapeutics to present data at the American Society of Clinical Oncology (ASCO) 2019 Annual Meeting on lead clinical candidate CPC634 in patients with solid tumors

May 17, 2019
Cristal Therapeutics, a clinical-stage pharmaceutical company developing targeted nanomedicines for the treatment of cancer and...
Read more
Cristal Therapeutics to present data at the American Society of Clinical Oncology (ASCO) 2019 Annual Meeting on lead clinical candidate CPC634 in patients with solid tumors

InteRNA and UMC Utrecht Publish Preclinical Evidence for Potential of miRNAs in Treatment of Epilepsy

May 15, 2019
- Journal of Neuroscience publication demonstrates that antagonizing miR-135a reduces seizures in chronic TLE model -
Read more
InteRNA and UMC Utrecht Publish Preclinical Evidence for Potential of miRNAs in Treatment of Epilepsy

A One-Two Punch for HPV-16-positive Cancers? 30 Apr 2019

April 30, 2019
ISA's phase 2 trial with lead product ISA101
Read more
A One-Two Punch for HPV-16-positive Cancers? 30 Apr 2019

Video interview with ISA CSO Prof. Dr. Cornelis Melief at AACR 2019

April 18, 2019
ecancer interview ISA's Chief Science Officer Prof. Dr. Kees Melief
Read more
Video interview with ISA CSO Prof. Dr. Cornelis Melief at AACR 2019

CRI Speaks with 2019 AACR-CRI Lloyd J. Old Award Recipient, Dr. Cornelis 'Kees' Melief

April 02, 2019
Cornelis J. M. 'Kees' Melief, M.D., Ph.D., received the 2019 AACR-CRI Lloyd J. Old Award in Cancer Immunology presented by the...
Read more
CRI Speaks with 2019 AACR-CRI Lloyd J. Old Award Recipient, Dr. Cornelis 'Kees' Melief

ISA Pharmaceuticals to Present Phase 2 Cervical Cancer Data at AACR Annual Meeting 2019

March 28, 2019
- Results from Phase 2 cervical cancer trial with ISA101 selected for plenary oral presentation
Read more
ISA Pharmaceuticals to Present Phase 2 Cervical Cancer Data at AACR Annual Meeting 2019

InteRNA Appoints Andrea van Elsas, Ph.D. to Scientific Advisory Board

March 25, 2019
--Co-inventor of original CTLA4-antibody and immuno-oncology innovator to expand the Company's clinical development expertise--...
Read more
InteRNA Appoints Andrea van Elsas, Ph.D. to Scientific Advisory Board

Modra Pharmaceuticals announces first patients treated in phase IIa metastatic breast cancer trial

March 21, 2019
Drug Name : docetaxel + ritonavir
Read more
Modra Pharmaceuticals announces first patients treated in phase IIa metastatic breast cancer trial

ISA Pharmaceuticals' Chief Scientific Officer Prof. Dr. Cornelis Melief Receives AACR-CRI Lloyd J. Old Award in Cancer Immunology 2019

March 19, 2019
- Recognition for outstanding and innovative cancer research
Read more
ISA Pharmaceuticals' Chief Scientific Officer Prof. Dr. Cornelis Melief Receives AACR-CRI Lloyd J. Old Award in Cancer Immunology 2019

Sapreme Technologies in a 6.8 M€ EU Alliance to Develop an Oligonucleotide Delivery Platform Based on Its Proprietary Endosomal Escape Enhancers

February 20, 2019
Sapreme Technologies has been awarded a 6.8 M€ grant by the European Union.
Read more
Sapreme Technologies in a 6.8 M€ EU Alliance to Develop an Oligonucleotide Delivery Platform Based on Its Proprietary Endosomal Escape Enhancers

Modra Pharmaceuticals Expands Management Team and Provides Corporate Update

December 19, 2018
-- Colin Freund has joined as CEO -- Dr. Edwin De Wit appointed Head of Oncology Development -- Dr. Alan Barge appointed Chai...
Read more
Modra Pharmaceuticals Expands Management Team and Provides Corporate Update
1 2 3 4 Next

Home > Press Releases > Archive

© 2020 Aglaia Oncology Funds | Privacy | Sitemap
Aglaia Oncology Funds